External validation of the American Joint Committee on Cancer melanoma staging system eighth edition using the surveillance, epidemiology, and end results program

2021 ◽  
Author(s):  
Angelina Tjokrowidjaja ◽  
Lois Browne ◽  
Hussein Soudy
Keyword(s):  
External Validation ◽  
Staging System ◽  
American Joint Committee ◽  
Eighth Edition ◽  
End Results

scholarly journals Survival of patients with early invasive melanoma down-staged under the new eighth edition of the American Joint Committee on Cancer staging system

2019 ◽  
Vol 80 (1) ◽  
pp. 272-274 ◽  
Author(s):  
Lena A. von Schuckmann ◽  
Maria Celia B. Hughes ◽  
Rebecca Lee ◽  
Paul Lorigan ◽  
Kiarash Khosrotehrani ◽  
...  
Keyword(s):  
Staging System ◽  
Cancer Staging ◽  
American Joint Committee ◽  
Eighth Edition

scholarly journals Prognostic Validity of the American Joint Committee on Cancer Eighth Edition Staging System for Well-Differentiated Pancreatic Neuroendocrine Tumors: A Retrospective Multinational Multicenter Study

2020 ◽  
Author(s):  
Hebin Wang ◽  
Ding Ding ◽  
Tingting Qin ◽  
Jun Liu ◽  
Hang Zhang ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Staging System ◽  
Tnm Staging ◽  
Stage I ◽  
Pancreatic Neuroendocrine Tumors ◽  
American Joint Committee ◽  
Staging Systems ◽  
Significant Difference ◽  
Well Differentiated ◽  
Eighth Edition

Abstract Background:There is no widely-accepted staging system for pancreatic neuroendocrine tumors (pNETs). The aim of this study was to validate the American Joint Committee on Cancer (AJCC) 8th edition staging system for well-differentiated (G1/G2) pNETs.Methods:A multicenter dataset (n=1086) was used to evaluate the application of the AJCC 7th and 8th, the European Neuroendocrine Tumor Society (ENETS), and the modified ENETS (mENETS) staging systems for well-differentiated pNETs.Results:The proportion of patients with stage III tumors was extremely low (1.1%) according to the AJCC 7th staging system. For the ENETS staging system, patients with stage IIIA disease had worse estimated mean survival than patients with stage IIIB disease (78.9 vs. 107.3 months). When comparing with patients in stage I, the AJCC 7th, ENETS, and mENETS staging systems showed good performance in discriminating between stages; however, there was no significant difference in some stages when the reference was defined as the earlier stage. When the reference was defined as stage I or the earlier stage, there was a significant inter-stage difference in the AJCC 8th staging system.Conclusions:The AJCC 8th staging system is more suitable for pNETs than other TNM staging systems and may be adopted in clinical practice.

scholarly journals External validation of the 8th American Joint Committee on Cancer staging system for gall bladder carcinoma

2018 ◽  
Vol 9 (6) ◽  
pp. 1084-1090
Author(s):  
Hani Oweira ◽  
Arianeb Mehrabi ◽  
Anwar Giryes ◽  
Aysun Tekbas ◽  
Omar Abdel-Rahman
Keyword(s):  
Gall Bladder ◽  
Bladder Carcinoma ◽  
External Validation ◽  
Staging System ◽  
Cancer Staging ◽  
Gall Bladder Carcinoma ◽  
American Joint Committee

scholarly journals Development and validation of nomogram combining serum biomarker for predicting survival in patients with resected rectal cancer

2019 ◽  
Vol 39 (11) ◽  
Author(s):  
Shaonan Fan ◽  
Ting Li ◽  
Ping Zhou ◽  
Qiliang Peng ◽  
Yaqun Zhu
Keyword(s):  
Rectal Cancer ◽  
Clinical Decision Making ◽  
Validation Cohort ◽  
External Validation ◽  
Staging System ◽  
Clinical Decision ◽  
Tnm Staging ◽  
P Value ◽  
Training Cohort ◽  
American Joint Committee

Abstract Purpose: Nomogram is a widely used tool that precisely predicts individualized cancer prognoses. We aimed to develop and validate a reliable nomogram including serum tumor biomarkers to predict individual overall survival (OS) for patients with resected rectal cancer (RC) and compare the predictive value with the American Joint Committee on Cancer (AJCC) stages. Patients and methods: We analyzed 520 patients who were diagnosed with non-metastatic rectal cancer as training cohort. External validation was performed in a cohort of 11851 patients from the Surveillance, Epidemiology, and End Results (SEER) database. Independent prognostic factors were identified and integrated to build a nomogram using the Cox proportional hazard regression model. The nomogram was evaluated by Harrell’s concordance index (C-index) and calibration plots in both training and validation cohort. Results: The calibration curves for probability of 1-, 3-, and 5-year OS in both cohorts showed favorable accordance between the nomogram prediction and the actual observation. The C-indices of the nomograms to predict OS were 0.71 in training cohort and 0.69 in the SEER cohort, which were higher than that of the seventh edition American Joint Committee on Cancer TNM staging system for predicting OS (training cohort, 0.71 vs. 0.58, respectively; P-value < 0.001; validation cohort, 0.69 vs. 0.57, respectively; P-value < 0.001). Conclusion: We developed and validated a novel nomogram based on CEA and other factors for predicting OS in patients with resected RC, which could assist clinical decision making and improvement of prognosis prediction for individual RC patients after surgery.

Sign in / Sign up

Export Citation Format

Share Document